i-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.
We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.
AdAlta is utilising the power of the i-body technology to create a pipeline of new drugs, with an initial focus on treating fibrotic diseases: i-bodies have exceptional targeting and antigen binding properties and carry out the functional role of recognising and binding to other molecules/antigens including disease targets to produce a therapeutic effect.
As unique compounds, i-bodies have long binding loop (see below) that is absent in other human antibodies and ‘next generation antibodies’. This unique combination of the long binding loop and the human protein i-body scaffold form the exciting new i-body.
i-body key properties and benefits
- Highly targeted with high affinity and specificity for their target
- Small proteins; 10% the size of a typical human antibody
- Highly stable to proteases, high temperatures and low pH
- Long loop for target cavity binding and alternative epitopes
- Human protein – reduces risk of an adverse immune response
i-bodies are unlike other drugs under development, with unique advantages
|Low toxicity: no off target effects|
|Alternative routes of administration|
|Easy to manufacture|
|Speed & risk of development|
Successfully reaching challenging targets
Unlike current antibody therapies, i-bodies recognise and bind to a diverse range of different therapeutically-relevant targets including those that are difficult/intractable to access such as G-protein coupled receptors (GPCRs) and ion channels.
G-protein coupled receptors (GPCRs) and ion channels have traditionally been targeted by small molecule drugs, which account for and are targeted by approximately 40% of all drugs currently on the market. But existing small molecules therapies can have an increased risk of toxicity and off target side effects due to their lack of specificity.
With their high affinity and specificity and long binding loop, the i-body can access GPCRs and ion channels without the off-target side effects common with some other small molecule drugs.
Learn more about i-bodies.